OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age

Trial Profile

OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 May 2016

At a glance

  • Drugs Cytarabine (Primary) ; Omacetaxine mepesuccinate (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 24 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Dec 2014 Planned number of patients changed from 37 to 60 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top